For pharmaceutical companies, Mercy Halo™ offers an opportunity to accelerate clinical development programs through exploratory sample analysis for key tumor-derived biomarkers. Future offerings will include patient screening for clinical trial enrollment and companion diagnostic development to support new drug commercialization.
Extracellular Vesicles in Early Cancer Detection
Robust peer-reviewed literature demonstrates the potential of EVs in early cancer detection.
I can do things you cannot, you can do things I cannot;
together we can do great things.